HGH Frag Peptide (176-191) (5 mg) OxyPharma

Catalogue entry: HGH Frag Peptide (176-191) OxyPharma. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

HGH Frag 176–191 is a source label referring to a region of human growth hormone rather than a complete pharmaceutical specification. The label must be checked against the actual sequence, modifications and chemical form. It should not be automatically renamed AOD9604 or treated as full-length growth hormone.

What the research measured

Heffernan and colleagues reported experiments with a synthetic GH fragment in the American Journal of Physiology in 2000, followed by AOD9604 mouse research in 2001. The compounds and experimental designs must remain distinct. Human findings for a modified analogue cannot establish the efficacy or safety of a differently specified fragment.

Sporting claims and limitations

Sporting discussions focus on fat metabolism while assuming fewer broader GH effects. A selected fragment sequence is not proof of selective clinical action or a favourable benefit-risk balance. CJC-1295 DAC stimulates a different part of the endocrine system and offers no evidence for this fragment. Neither a mechanism comparison nor a related name demonstrates improved body composition or athletic performance.

Product identity and documentation

For this catalogue item, the most informative documents define what the label actually denotes. Check the full sequence, any terminal changes, relevant chemical form and batch-specific identity test. A report stating only peptide purity is insufficient to compare the material with a named study. The quantity selected above is labelled content, not an established administration amount or confirmation of clinical equivalence.